Aurinia Pharmaceuticals Inc. reported significant financial performance improvements in its latest 10-Q filing for the second quarter of 2026. The company achieved total revenue of $83.2 million for the three months ended June 30, 2026, a 19% increase from $70.0 million in the same period of 2025. For the first half of 2026, total revenue reached $160.9 million, up 21% from $132.5 million year-over-year. The increase was primarily driven by net product sales of LUPKYNIS, which amounted to $79.4 million for the quarter and $153.0 million for the six months, reflecting a 19% and 21% rise, respectively, compared to the previous year.
Operating expenses for the second quarter decreased to $36.9 million from $49.9 million in the prior year, contributing to a substantial increase in income from operations, which rose to $46.3 million from $20.1 million. The net income for the quarter was $37.4 million, compared to $21.5 million in the same quarter of 2025. This resulted in earnings per share of $0.29 for the second quarter, up from $0.16 a year earlier. The company also reported a significant improvement in cash flows from operating activities, which increased by 87% to $85.1 million for the first half of 2026.
Aurinia's strategic developments included the acquisition of Kezar Life Sciences, completed on May 11, 2026, for approximately $55.5 million. This acquisition is expected to enhance Aurinia's portfolio in autoimmune disease therapies. The company has also initiated a Phase 4 study, PRESERVE, to investigate the combination of LUPKYNIS with other biologic agents in lupus nephritis patients, further expanding its clinical research efforts.
As of June 30, 2026, Aurinia's total assets increased to $792.3 million from $751.6 million at the end of 2025, bolstered by cash and cash equivalents of $179.8 million, up from $80.2 million. The company’s total liabilities rose slightly to $177.4 million, while shareholders' equity increased to $614.9 million, reflecting a strong financial position. The company continues to focus on expanding its market share and product adoption rates, particularly for LUPKYNIS, which is sold through specialty pharmacies and a collaboration with Otsuka Pharmaceutical.
Looking ahead, Aurinia anticipates continued growth driven by its commercialization efforts for LUPKYNIS and ongoing clinical development of its pipeline products. The company expects to fund future operations through existing cash and cash flows from operating activities, while also considering additional capital raises if necessary. The management remains optimistic about the potential for further revenue growth and market expansion in the coming quarters.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet needs. Its core product, LUPKYNIS (voclosporin), is the first FDA-approved oral treatment for adult lupus nephritis, marketed in the U.S. and licensed internationally. Aurinia develops novel immunosuppressants like AUR200 targeting B cell pathways. The company operates through direct sales and partnerships, leveraging proprietary patents and contract manufacturing to serve patients and healthcare providers globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov